To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
The primary objective is to determine the maximum tolerated dose (MTD), safety, and tolerability of oral CEP-37440 administered daily to patients with advanced or metastatic solid tumors.
Solid Tumors
DRUG: CEP-37440
Response Evaluation Criteria in Solid Tumors (RECIST v1.1), 8 months
Time to Response (TTR), The time interval from the date of first dose to the first documented response (complete or partial response), 8 months|Number of participants with adverse events, From signing of the informed consent to the end of the follow-up visit (approximately Month 10)|Time to Progression (TTP), The time interval from date of first dose to first documented disease progression, 8 months|Progression-free Survival (PFS), Time interval from date of first does to first documented disease progression or death from any cause (whichever occurs first), 10 months|Time to New Metastases (TTNM), Time interval from date of first dose to first documented new metastatic lesion not reported at baseline, 8 months
The primary objective is to determine the maximum tolerated dose (MTD), safety, and tolerability of oral CEP-37440 administered daily to patients with advanced or metastatic solid tumors.